Compounds > n-(4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl)-n'-(2-nitrobenzoyl)urea
Page last updated: 2024-09-03

n-(4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl)-n'-(2-nitrobenzoyl)urea and Abnormalities, Autosome

n-(4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl)-n'-(2-nitrobenzoyl)urea has been researched along with Abnormalities, Autosome in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ando, N; Iwai, M; Kagitani, Y; Kawabata, Y; Masuda, H; Nakajima, T; Tsukagoshi, S; Watanabe, M; Yamada, N1

Other Studies

1 other study(ies) available for n-(4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl)-n'-(2-nitrobenzoyl)urea and Abnormalities, Autosome

ArticleYear
Antimicrotubule effects of the novel antitumor benzoylphenylurea derivative HO-221.
    Cancer chemotherapy and pharmacology, 1995, Volume: 37, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Chromosome Aberrations; Cricetinae; Humans; Male; Metaphase; Mice; Mice, Inbred ICR; Micronucleus Tests; Microtubules; Nitrobenzenes

1995